Gilead Wins HIV Patent Suit, Nabs Oncology and Inflammation Startup

[{"selector":"#anim-871ec071-9593-4937-9b90-6e085be7c8e6","keyframes":{"opacity":[0,1]},"delay":0,"duration":1200,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-7aac2b71-2d22-4dbd-b7a6-6c2ab7b3bdf7","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

1. Gilead Sciences won a patent lawsuit regarding their HIV prevention medicines Truvada and Descovy.

[{"selector":"#anim-a4790338-b2c8-449b-9208-1751fdcd65e8","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

2. A Delaware jury ruled that the government's patents were invalid and did not infringe on them.

[{"selector":"#anim-225ada1e-aa70-4ee2-bfa8-ce49774d0e4c","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

3. The jury found that the government did not provide enough evidence showing patent violations by using Truvada or Descovy for HIV prevention.

[{"selector":"#anim-55070f93-9b5a-4ca0-be1f-76f534cb06c9","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

4. Gilead proved that all three patent claims were invalid, according to the jury.

[{"selector":"#anim-139727d1-257c-48bd-b767-6ee5b6bddeda","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

5. Truvada and Descovy prevent HIV replication and were approved for treatment and prevention.

[{"selector":"#anim-ad35ca4a-753e-403e-96ef-17ae1da56454","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

6. The Trump administration sued Gilead over PrEP approvals in November 2019.

[{"selector":"#anim-3239ecfb-09fc-44b0-b4ae-5b8719af9d27","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

7. Gilead acquired XinThera, a San Diego biotech, which gives them rights to small molecule inhibitors for oncology and inflammatory diseases.

[{"selector":"#anim-a51678c4-5406-4d6b-ad80-94b545a3e855","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

8. XinThera's PARP1 inhibitors have the potential for combo treatments with other molecules in Gilead's portfolio.

[{"selector":"#anim-3a5cf1d3-3341-4781-a9ad-b105fd3da057","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

9. Gilead's Trodelvy was approved in 2020 for metastatic triple-negative breast cancer.

[{"selector":"#anim-227c0a6a-faa2-4705-9cfc-d14a5aa243db","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

10. Once-dropped drugs make lucrative comebacks in the pharmaceutical industry.

[{"selector":"#anim-ec1af420-ed1a-4953-8624-7e9bd4fe2b85","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

Swipe up for more BIOMARKER news!

[{"selector":"#anim-efad5e74-3d16-4b23-965b-4e2226197dba","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Learn more